A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancer [0.03%]
一项关于DESTINY-Breast01真实世界单中心队列中乳腺癌患者接受德鲁替康治疗耐受性的研究
Ameer Basta,Kyle Lien,Weihong Sun et al.
Ameer Basta et al.
Introduction: The DESTINY-B01 trial led to trastuzumab deruxtecan (T-DXd) approval for human epidermal growth factor receptor-2 (HER2+) metastatic breast cancers (mBCs), with efficacy further confirmed by DESTINY-B03, dem...
Impact of comorbidity on antiemetic efficacy in patients with esophageal cancer treated with cisplatin-based chemotherapy: A retrospective study from Japan [0.03%]
日本以顺铂为基础的化疗治疗食管癌患者合并症对止吐疗效影响的回顾性研究
Masahiro Hatori,Shota Fukuoka,Shunya Kimura et al.
Masahiro Hatori et al.
Introduction: Cancer patients often have comorbidities due to the aging population or various other factors. However, clinical trials typically exclude specific severe comorbidities, and no prior study has examined their ...
Design of a neonatal orthotopic metastatic xenograft model of hepatoblastoma in mice [0.03%]
小鼠新生代肝母细胞瘤肺转移异种移植模型的建立
Pierre Klein,Hélène Guillorit,Léa Mora Charrot et al.
Pierre Klein et al.
Introduction: Hepatoblastoma (HB) is the most frequent liver cancer in children, typically occurring before the age of five. Thanks to the combination of chemotherapy and surgery, the five-year survival rate following dia...
Comparative Safety and Effectiveness of Azacitidine Plus Venetoclax Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score-Matched Analysis [0.03%]
阿扎胞苷联合维奈克拉与强化疗治疗急性髓系白血病的比较安全性和有效性：倾向性评分匹配分析
Yu-Cheng Chang,Hao-Kuen Lin,Yu-Che Lee et al.
Yu-Cheng Chang et al.
There is limited data comparing Azacitidine plus Venetoclax (HMA&Ven) versus traditional intensive chemotherapy with Cytarabine plus Anthracycline (IC) in older patients. We conducted a propensity score-matched cohort study using the TriNet...
Ignacio Antonio Tapia-Salas,Rita Dorantes-Heredia,Rodrigo Rafael Flores-Mariñelarena et al.
Ignacio Antonio Tapia-Salas et al.
Prostate cancer is one of the main types of cancer in men, specifically in Mexico there is an increasing trend in incidence in the last two decades. The lack of targeted therapy in this neoplasm compels us to find new biomarkers that could ...
Preclinical Evaluation of 99mTc-Labeled LHRH Analog as Cancer Receptor Imaging [0.03%]
茋标记的LHRH类似物作为癌症受体显像剂的临床前评价研究
Lucía Alfaya,Ximena Camacho,Mirel Cabrera et al.
Lucía Alfaya et al.
Introduction: Breast cancer is the main cause of cancer-related mortality in women in the developed world. In particular, receptors of luteinizing hormone-releasing hormone (LHRH or GnRH) are overexpressed in this maligna...
Unsupervised dynamic ePRO reporting of immunotherapy related symptoms in cancer patients [0.03%]
用于癌症患者免疫治疗相关症状的无监督动态ePRO报告系统
Anna Kristina Stauffacher,Louise von Stockar,Hans-Friedrich Witschel et al.
Anna Kristina Stauffacher et al.
Introduction: The use of electronic patient reported outcome (ePRO) in patients has been demonstrated to improve patient care and symptom management in curative and palliative settings. We examined the electronic and dyna...
Prognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study [0.03%]
HALP评分在转移性间皮瘤中的预后价值：一项回顾性研究
Ozlem Dogan,Yakup Duzkopru,Tulay Eren
Ozlem Dogan
Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status,...
Efficacy and Safety of Chemotherapy Combined with Anlotinib in Advanced EGFR-mutant NSCLC with Primary Resistance to EGFR-TKIs：a retrospective cohort Study [0.03%]
阿帕替尼联合化疗治疗EGFR突变阳性TKI耐药晚期非小细胞肺癌回顾性研究
Yonghong Li,Yirui Liu,Yi Peng et al.
Yonghong Li et al.
Objective: To explore effective treatment strategies for EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitors) primary resistant advanced non-small cell lung cancer (NSCLC). ...
The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-term Therapeutic Efficacy: A Multicenter Analysis [0.03%]
阿特朱单抗联合贝伐珠单抗治疗不可切除肝细胞癌的中性粒细胞与淋巴细胞比值预测长期疗效：多中心分析
Ryo Sato,Takanori Suzuki,Kentaro Matsuura et al.
Ryo Sato et al.
Introduction: Atezolizumab plus bevacizumab (ATZ/BEV) is used for the treatment of unresectable hepatocellular carcinoma (u-HCC). However, there are few reports investigating the predictors of whether or not disease contr...